Literature DB >> 10794303

Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.

I Mendez1, A Dagher, M Hong, A Hebb, P Gaudet, A Law, S Weerasinghe, D King, J Desrosiers, S Darvesh, T Acorn, H Robertson.   

Abstract

The authors have studied the ability of glial cell line-derived neurotrophic factor (GDNF) to promote survival of human fetal dopaminergic tissue after a storage period of 6 days and subsequent implantation into the human putamen. The results indicate that GDNF promotes survival of stored dopaminergic cells. Cells stored without GDNF had a 30.1% decrease in survival time compared with those exposed to GDNF. Two patients with Parkinson's disease received bilateral putaminal implants of fetal dopaminergic cells exposed to GDNF for 6 days and showed enhancement of graft survival as assessed by positron emission tomography scanning. A mean increase of 107% in putaminal fluorodopa uptake from baseline values was observed 12 months postgrafting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794303     DOI: 10.3171/jns.2000.92.5.0863

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  31 in total

1.  Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Bull       Date:  2005-09-26       Impact factor: 4.077

2.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 3.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

4.  Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Brian F Daley; Timothy J Collier
Journal:  Exp Neurol       Date:  2015-02-12       Impact factor: 5.330

Review 5.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

Review 6.  Dopamine cell transplantation in Parkinson's disease: challenge and perspective.

Authors:  Yilong Ma; Shichun Peng; Vijay Dhawan; David Eidelberg
Journal:  Br Med Bull       Date:  2011-08-28       Impact factor: 4.291

7.  Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants.

Authors:  K Mukhida; K A Baker; D Sadi; I Mendez
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

8.  Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.

Authors:  Deyi Duan; Hui Yang; Jingzhong Zhang; Jinlu Zhang; Qunyuan Xu
Journal:  Exp Brain Res       Date:  2004-10-12       Impact factor: 1.972

9.  The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease.

Authors:  Nathalie Breysse; Thomas Carlsson; Christian Winkler; Anders Björklund; Deniz Kirik
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

Review 10.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.